IXCELLS BIOTECHNOLOGIES

Company Snapshot

Founded: 2014
Entity Type: Private
Region: U.S.
Headquarter: California, U.S.
Key Geographics: North America
Corporate Address: 10100 Willow Creek Road, San Diego, California 92131, U.S. Tel.: +1-858-412-5988 Web.: www.ixcellsbiotech.com

Company Overview

iXCells Biotechnologies is a company that specializes in providing a wide range of human and animal cell lines. Their cell lines include skeletal muscle myoblasts, neurons, astrocytes, human neural stem cells, and more, all of which are derived from iPSCs. Induced pluripotent stem cells (iPSCs) and their derived cell types can be obtained from both healthy donors and patients with particular diseases, enabling researchers to study disease models in vitro. The company provides primary cell and stem cell solutions for research related to drug discovery, disease modeling, cell therapy, toxicity testing and personalized medicine.

IXCELLS BIOTECHNOLOGIES In Reports

Global Cell Line and Membrane Market

According to BCC Research Cell Line and Membrane Market report includes global revenue ($ Million) for base year data 2024 and estimated data for the forecast period 2025 through 2030.

Cell Line and Membrane Market

The global cell line and membrane market should reach $220.3 million by 2023 from $172.0 million in 2018 at a compound annual growth rate of 5.1% for the period 2018 to 2023.

Genome Editing: Technologies and Global Markets

The global market for genome editing should grow from $1.4 billion in 2018 to $4.4 billion by 2023, with a compound annual growth rate (CAGR) of 25.7% for the period of 2018-2023.

Company's Business Segments

  • Preclinical Drug Discovery Solutions : The company offers high-quality primary cells, iPSC-derived cells, reagents, and custom pre-clinical drug discovery services.

Applications/End User Industries

  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes
  • CROs (Contract Research Organizations) and Toxicology Labs
  • Life Sciences
  • Regenerative Medicine & Precision Medicine Firms
AI Sentiment